Vaxcyte doses first participants in OPUS-3 trial

Vaxcyte (PCVX) announced that the first participants were dosed in the OPUS-3 Phase 3 trial evaluating VAX-31, the company’s next-generation 31-valent pneumococcal conjugate vaccine candidate, in adults who have previously received pneumococcal vaccination. This trial is evaluating the safety, tolerability and immunogenicity of VAX-31, including whether VAX-31 can boost serotype-specific immune responses, while providing the broadest coverage in a single vaccine in this adult population.